XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
XCSport体育:Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
XCSport体育:Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
XCSport体育:Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
XCSport体育:Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
XCSport体育:Science & Technology
R&D Result
XCSport体育:Innovation Centre
XCSport体育:Technology Platform
XCSport体育:Quality Management
Manufacturing
XCSport体育:Collaborations
XCSport体育:Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
XCSport体育:Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
XCSport体育:Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
XCSport体育:Contact Us
XCSport体育:Contact Information
Customer Message
Privacy
Legal Statement
Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
XCSport体育:Popular Science
Highlights
Download
Media Reports
XCSport体育:Media Enquiry
2026-07-25
Henlius to Present Latest Results on ADC and IO Therapies in Lung Cancer at 2025 WCLC
2026-07-14
Henlius’ HLX22 International Multicentre Phase 3 Head-to-Head Trial Administers First Dose to US Patient in HER2+ GC
2026-07-09
Henlius Receives Global Regulatory Approvals for Phase 2 MRCT of Its PD-L1 ADC HLX43 on NSCLC
2026-07-02
Henlius Receives New EMA GMP Certification, Accelerating European Market Entry of Two Biosimilar Candidates
2026-07-02
Henlius and HanchorBio Collaborate to Develop Novel SIRPα-Fc Fusion Protein, Expanding Tumor Immunotherapy Layout
2026-06-26
Henlius Hosts Investigator Meeting for Bridging Study of Serplulimab in Japan
2026-06-25
Henlius Doses First Patient in Japanese Bridging Study of Serplulimab for Extensive-Stage Small Cell Lung Cancer
2026-06-24
Serplulimab Approved in the UK and India for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
2026-06-20
Henlius Shines at 2025 BIO International Convention, Showcasing Its Innovative Achievements
1
2
3
...
7